BCL2 and cancer: Many of the drugs currently used in cancer therapy mediate, at least in part, their cytotoxic effects through activation of the BCL-2-controlled apoptotic pathway; however key initiators of this pathway, such as TP53, are very frequently altered in cancer, creating a mechanism of drug resistance.